IBDEI35I ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50316,1,4,0)
 ;;=4^E05.90
 ;;^UTILITY(U,$J,358.3,50316,2)
 ;;=^5002492
 ;;^UTILITY(U,$J,358.3,50317,0)
 ;;=E05.91^^193^2490^40
 ;;^UTILITY(U,$J,358.3,50317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50317,1,3,0)
 ;;=3^Thyrotoxicosis,Unspec w/ Thyrotoxic Crisis/Storm
 ;;^UTILITY(U,$J,358.3,50317,1,4,0)
 ;;=4^E05.91
 ;;^UTILITY(U,$J,358.3,50317,2)
 ;;=^5002493
 ;;^UTILITY(U,$J,358.3,50318,0)
 ;;=E89.0^^193^2490^32
 ;;^UTILITY(U,$J,358.3,50318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50318,1,3,0)
 ;;=3^Postprocedural Hypothyroidism
 ;;^UTILITY(U,$J,358.3,50318,1,4,0)
 ;;=4^E89.0
 ;;^UTILITY(U,$J,358.3,50318,2)
 ;;=^5003035
 ;;^UTILITY(U,$J,358.3,50319,0)
 ;;=E03.2^^193^2490^13
 ;;^UTILITY(U,$J,358.3,50319,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50319,1,3,0)
 ;;=3^Hypothyroidism d/t Meds/Oth Exogenous Substances
 ;;^UTILITY(U,$J,358.3,50319,1,4,0)
 ;;=4^E03.2
 ;;^UTILITY(U,$J,358.3,50319,2)
 ;;=^5002471
 ;;^UTILITY(U,$J,358.3,50320,0)
 ;;=E03.9^^193^2490^14
 ;;^UTILITY(U,$J,358.3,50320,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50320,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,50320,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,50320,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,50321,0)
 ;;=E06.0^^193^2490^36
 ;;^UTILITY(U,$J,358.3,50321,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50321,1,3,0)
 ;;=3^Thyroiditis,Acute
 ;;^UTILITY(U,$J,358.3,50321,1,4,0)
 ;;=4^E06.0
 ;;^UTILITY(U,$J,358.3,50321,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,50322,0)
 ;;=E06.1^^193^2490^37
 ;;^UTILITY(U,$J,358.3,50322,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50322,1,3,0)
 ;;=3^Thyroiditis,Subacute
 ;;^UTILITY(U,$J,358.3,50322,1,4,0)
 ;;=4^E06.1
 ;;^UTILITY(U,$J,358.3,50322,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,50323,0)
 ;;=C73.^^193^2490^19
 ;;^UTILITY(U,$J,358.3,50323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50323,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,50323,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,50323,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,50324,0)
 ;;=E16.2^^193^2490^10
 ;;^UTILITY(U,$J,358.3,50324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50324,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,50324,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,50324,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,50325,0)
 ;;=E20.0^^193^2490^15
 ;;^UTILITY(U,$J,358.3,50325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50325,1,3,0)
 ;;=3^Idiopathic Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,50325,1,4,0)
 ;;=4^E20.0
 ;;^UTILITY(U,$J,358.3,50325,2)
 ;;=^5002712
 ;;^UTILITY(U,$J,358.3,50326,0)
 ;;=E20.9^^193^2490^11
 ;;^UTILITY(U,$J,358.3,50326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50326,1,3,0)
 ;;=3^Hypoparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,50326,1,4,0)
 ;;=4^E20.9
 ;;^UTILITY(U,$J,358.3,50326,2)
 ;;=^5002714
 ;;^UTILITY(U,$J,358.3,50327,0)
 ;;=E23.0^^193^2490^12
 ;;^UTILITY(U,$J,358.3,50327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50327,1,3,0)
 ;;=3^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,50327,1,4,0)
 ;;=4^E23.0
 ;;^UTILITY(U,$J,358.3,50327,2)
 ;;=^60685
 ;;^UTILITY(U,$J,358.3,50328,0)
 ;;=E27.1^^193^2490^34
 ;;^UTILITY(U,$J,358.3,50328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50328,1,3,0)
 ;;=3^Primary Adrenocortical Insufficiency
 ;;^UTILITY(U,$J,358.3,50328,1,4,0)
 ;;=4^E27.1
 ;;^UTILITY(U,$J,358.3,50328,2)
 ;;=^5002740
 ;;^UTILITY(U,$J,358.3,50329,0)
 ;;=E27.2^^193^2490^1
